EDO has demonstrated the ability to move multiple programmes from licensing-in to investigational new drug status in just two years, significantly improving typical pharmaceutical development timelines at reduced cost. Additionally, the management team is currently executing early clinical trials, including clinical proof-of-concept.
EDO conducts research and early development studies with academic and clinical researchers worldwide. The company is particularly interested in working with biotech companies with novel molecules for licensing-in opportunities, and with leading researchers and clinical specialists to study novel drugs in unique preclinical models and in clinical studies enriched with biomarker and diagnostic tools.
Click a logo to see more information.